Collegium Pharmaceutical, Inc.(COLL)

Description: Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, focuses on developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its lead product candidate is Xtampza, an abuse-deterrent, extended-release, oral formulation of oxycodone, a prescribed opioid medication. The company is also developing COL-172, an abuse-deterrent, extended-release oxymorphone for the treatment of chronic pain; COL-195, an abuse-deterrent, extended-release hydrocodone for the treatment of chronic pain; COL-196, a morphine formulation for the treatment of pain; and COL-171, a proprietary preclinical DETERx extended-release, abuse-deterrent methylphenidate formulation for the treatment of attention deficit hyperactivity disorder. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Canton, Massachusetts.

---

Keywords: Pharmaceutical Disease Pain Organic Compounds Euphoriants Chemical Compounds Chronic Pain Opioids Platform Technology Ethers Morphinans Phenols Attention Deficit Hyperactivity Disorder Hyperactivity Disorder Morphine Oxycodone Methylphenidate Treatment Of Chronic Pain Hydrocodone Oxymorphone Treatment Of Attention Deficit Hyperactivity Disorder

---

Home Page: www.collegiumpharma.com

COLL Technical Analysis

100 Technology Center Drive
Stoughton, MA 02072
United States
Phone: 781 713 3699

---

Officers

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)